echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > The State Food and Drug Administration conditionally approved the marketing of mobosetinib succinate capsules

    The State Food and Drug Administration conditionally approved the marketing of mobosetinib succinate capsules

    • Last Update: 2023-02-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, the State Medical Products Administration (NMPA) conditionally approved the listing of Mobosetinib succinate capsules (trade name: ENVIRIX/EXKIVITY) declared by Takeda Pharmaceutical Co.
    , Ltd.
    through the priority review and approval process
    .
    It is indicated for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) who progress during or after platinum-containing chemotherapy and carry an epidermal growth factor receptor (EGFR) exon 20 insertion mutation
    .
    Mobosetinib is an irreversible tyrosine kinase inhibitor
    targeting EGFR exon 20 insertion mutations.
    The launch of this drug provides a new treatment option
    for patients with advanced non-small cell lung cancer who carry EGFR exon 20 insertion mutation positive.
    ={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
    appendChild(createElement('script')).
    src='http://bdimg.
    share.
    baidu.
    com/static/api/js/share.
    js?v=89860593.
    js?cdnversion='+~(-new Date()/36e5)];
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.